First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.

First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.

<h4>Background</h4>Current therapies for cutaneous leishmaniasis are limited by poor efficacy, long-term course of treatment, and the development of resistance. We evaluated if pentavalent antimony (an anti-parasitic drug) combined with imiquimod (an immunomodulator) was more effective t...

Full description

Bibliographic Details
Main Authors: Cesar Miranda-Verastegui, Gianfranco Tulliano, Theresa W Gyorkos, Wessmark Calderon, Elham Rahme, Brian Ward, Maria Cruz, Alejandro Llanos-Cuentas, Greg Matlashewski
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-07-01
Series:PLoS Neglected Tropical Diseases
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19636365/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19636365/?tool=EBI

Similar Items